1. Generics Bulletin

ANI eyes more deals to follow WellSpring

ANI Pharmaceuticals is looking for further deals to accompany the US firm’s organic growth, according to president and chief executive Arthur Przybyl. In August, ANI acquired for US$18 million Canada-based WellSpring Pharma Services, in a bid to expand its contract manufacturing and development business, and to increase the US firm’s capacity to re-commercialise its pipeline of ANDAs that require a technology transfer from its local Baudette facility in Minnesota (Generics bulletin, 31 August 2018, page 14).

ANI Pharmaceuticals is looking for further deals to accompany the US firm’s organic growth, according to president and chief executive Arthur Przybyl. In August, ANI acquired for US$18 million Canada-based WellSpring Pharma Services, in a bid to expand its contract manufacturing and development business, and to increase the US firm’s capacity to re-commercialise its pipeline of ANDAs that require a technology transfer from its local Baudette facility in Minnesota (Generics bulletin, 31 August 2018, page 14).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

Roche Suggests Perjeta Biosimilars May Not Hit Until 2027 ‘Or Later’

 
• By Dean Rudge

Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.